Immune thrombocytopenia (ITP) trials in Spain
15 of 16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleStudy to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
- Where
- Barcelona, Burgos, Madrid, Murcia, Palma, Salamanca, San Cristóbal de La Laguna, Sevilla
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Sanofi
See details and how to joinNCT07007962 · EU 2025-522070-36-00 - Phase 1/2Taking peopleTGD001 Treatment in Thrombotic Microangiopathies
- Where
- Valencia
- Age
- 18 years and over
- People
- 70
- Run by
- TargED Biopharmaceuticals B.V.
See details and how to joinNCT07459114 - Phase 1/2Taking peopleA Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
- Where
- Barcelona, Burgos, Madrid, Murcia, Pamplona
- Age
- 18 years to 64 years
- People
- 68 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06721013 · EU 2024-518502-40-00 - Phase 3Taking peopleA Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Where
- Alcorcón, Madrid, Salamanca, Sevilla
- Age
- 18 years and over
- People
- 171 worldwide
- Run by
- Takeda
See details and how to joinNCT06722235 · EU 2024-514401-54-00 - Phase 1Taking peoplePhase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
- Where
- Barcelona, Córdoba, Madrid, Pamplona, Sevilla, Valencia
- Age
- 18 years and over
- People
- 78 worldwide
- Run by
- Chugai Pharmaceutical Co. Ltd.
See details and how to join2024-511346-39-00 - Phase 3Taking peopleA Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Where
- Alcorcón, Burgos, Madrid, Salamanca, Sevilla
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- Takeda
See details and how to joinNCT06948318 · EU 2025-521692-31-00 - Phase 2Taking peopleStudy to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
- Where
- Badalona, Madrid
- Age
- 18 years and over
- People
- 56 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07104565 · EU 2025-521286-27-00 - Phase 3Taking peopleA Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
- Where
- A Coruña, Madrid
- Age
- 18 years to 70 years
- People
- 40 worldwide
- Run by
- Kedrion S.p.A.
See details and how to joinNCT07059000 · EU 2023-507115-35-00 - Phase 1/2Taking peopleSafety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
- Where
- Barcelona, Córdoba, Madrid, Seville
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- CRISPR Therapeutics AG
See details and how to joinNCT07549698 - Phase 2/3Taking peopleA Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
- Where
- Barcelona, Esplugues de Llobregat, Madrid, Sabadell, Zaragoza
- Age
- 12 years to 17 years
- People
- 24 worldwide
- Run by
- argenx
See details and how to joinNCT07194850 · EU 2025-521055-23-00 - Phase 2Taking peopleSafety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
- Where
- Barcelona, Burgos, Murcia, Salamanca
- Age
- 18 years to 80 years
- People
- 30 worldwide
- Run by
- Nuvig Therapeutics, Inc.
See details and how to joinNCT07095127 · EU 2024-520359-26-00 - Phase 1Taking peoplePhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- Where
- Barcelona, Córdoba, Madrid, Pamplona, Sevilla, Valencia
- Age
- 18 years to 85 years
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00 - Phase 1Enrolling by invitationPhase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
- Where
- Barcelona, Córdoba, Madrid, Pamplona, Seville, Valencia
- Age
- 18 years to 85 years
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06723106 - Phase 3Taking peopleA Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
- Where
- A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pozuelo de Alarcón, Valencia
- Age
- 18 years and over
- People
- 69 worldwide
- Run by
- argenx
See details and how to joinNCT06544499 · EU 2024-515451-38-00 - Phase 1/2Taking peopleA Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
- Where
- Burgos, Madrid, San Pedro, Valencia
- Age
- 18 years and over
- People
- 24 worldwide
- Run by
- Climb Bio, Inc.
See details and how to joinNCT07043946